| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8e071d18fea054bf8d1420d483e78ed1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eb9c6b40161bafe7bd55f0b4defcea04 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39541
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| filingDate |
2016-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c77282dc6d0d12a970ebfe1dc1d6ce0b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_48ff6cc298790973df0dfe66543c7202
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_922ede0e9afc487b566f6dc613b21590
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d0cb36e98e8867f3071e70f5d03d61f2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_391db0deba8c8ea5d5cc36a4bd193698
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_da357e9ec6e204904318ac0409482a24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3b666aef4aa7cee89160893e1f5d42e1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dc684918466ede68e0181f1787a3bdc1 |
| publicationDate |
2018-06-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3328418-A1 |
| titleOfInvention |
Combination therapies comprising antibody molecules to pd-1 |
| abstract |
Combination therapies comprising antibody molecules that specifically bind to PD-1 disclosed. The combination therapies can be used to treat or prevent cancerous or infectious conditions and disorders. |
| priorityDate |
2015-07-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |